{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Genotype+1&page=9", "query": { "condition": "Hepatitis C Genotype 1", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 201, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Genotype+1&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Genotype+1&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T21:52:24.334Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01142700", "title": "A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus Genotype 1" ], "interventions": [ { "name": "BMS-824393", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon Alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2010-07", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2011-03-15", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 11, "location_summary": "Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142700" }, { "nct_id": "NCT02378935", "title": "Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "VOX", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2015-02-17", "completion_date": "2016-04-12", "has_results": true, "last_update_posted_date": "2020-03-06", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 31, "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02378935" }, { "nct_id": "NCT01225380", "title": "A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection" ], "interventions": [ { "name": "GS-9190", "type": "DRUG" }, { "name": "GS-9256", "type": "DRUG" }, { "name": "Pegasys®", "type": "BIOLOGICAL" }, { "name": "Copegus®", "type": "DRUG" }, { "name": "GS-9190 placebo", "type": "DRUG" }, { "name": "GS-9256 placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 324, "start_date": "2010-10", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-01-28", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01225380" }, { "nct_id": "NCT01221298", "title": "A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HCV", "Chronic Hepatitis C Infection", "Hepatitis C Genotype 1" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-072", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2010-10", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 4, "location_summary": "Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01221298" }, { "nct_id": "NCT01297270", "title": "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI201335", "type": "DRUG" }, { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 658, "start_date": "2011-04", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-09-18", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01297270" }, { "nct_id": "NCT01399619", "title": "Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "PegIFN/RBV", "type": "DRUG" }, { "name": "BI201335", "type": "DRUG" }, { "name": "BI201335 24W", "type": "DRUG" }, { "name": "Bi 201335", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 310, "start_date": "2011-09", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-08-29", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Palm Springs, California • San Francisco, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399619" }, { "nct_id": "NCT03407703", "title": "Hepatitis C (HCV) Cure and Kidney Health", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Elbasvir / Grazoprevir Oral Tablet [Zepatier]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "San Francisco Veterans Affairs Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-03-27", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2018-04-18", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03407703" }, { "nct_id": "NCT01467479", "title": "A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "BIOLOGICAL" }, { "name": "Highly Active Antiretroviral Therapy (HAART)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 185, "start_date": "2011-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-03-17", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467479" }, { "nct_id": "NCT01405027", "title": "Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C", "Genotype 1" ], "interventions": [ { "name": "Educational Intervention", "type": "PROCEDURE" }, { "name": "Patient education and management skills training", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Chronic Liver Disease Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2011-12", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-01-06", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 43, "location_summary": "Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Calabasas", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01405027" }, { "nct_id": "NCT01058512", "title": "A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "NOV-205", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 22, "start_date": "2010-03", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-10-10T21:52:24.334Z", "location_count": 6, "location_summary": "Jacksonville, Florida • Miami, Florida • Orlando, Florida + 3 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Framingham", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01058512" } ] }